This year, two Milton Park based companies, Grey Wolf Therapeutics and Adaptimmune, are in the running for the award for ‘Best Established Biotech Company’ at the 16th Annual OBN Awards due to take place in London on 20 November.
Hosted by occupier OBN, a not-for-profit membership organisation which helps innovative life science start ups to thrive, the event highlights and celebrates companies of all sizes making significant contributions and progress in life sciences.
Grey Wolf Therapeutics is advancing novel antigen modulation technology which controls T cells to guide the immune system. The occupier is progressing a new class of antigen modulators through the clinic, developed to treat disease by controlling T cell activation. It is headquartered in the Innovation Centre and is part of the M:M Bio ecosystem, alongside Pathios Therapeutics and ThirtyFiveBio.
Adaptimmune is working to redefine the treatment of solid tumour cancers with cell therapy. Its approach is personalised from discovery through to delivery, with fully integrated capabilities including research, global clinical development, translational sciences, commercialisation and manufacturing.
Milton Park is sponsoring the OBN Award for ‘Best Start up Biotech Company’. Congratulations to the fantastic companies announced as finalists in this category: Ambrose Healthcare, CamGene Therapeutics and Tessellate BIO.
We look forward to finding out who the winners are and wish all finalists the best of luck.
Image: ©OBN (UK) Ltd. All Rights Reserved.
Sign up to our newsletter
Subscribe